Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina et al
- PMID: 32816687
- DOI: 10.1136/annrheumdis-2020-218147
Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina et al
Keywords: ankylosing; antirheumatic agents; arthritis; biological therapy; infectious; rheumatoid; spondylitis.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.Ann Rheum Dis. 2021 May;80(5):e79. doi: 10.1136/annrheumdis-2020-218029. Epub 2020 Aug 18. Ann Rheum Dis. 2021. PMID: 32816688 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical